BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy

SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD

Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD

Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications

Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD

Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD

Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

What to Expect From These Drug/Biotech Players This Earnings Season?

Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?

One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?

Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights

Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq - FOLD)

What's Going On With BioMarin Stock On Tuesday?

BioMarin: Amicus Buyout Sparks My Enthusiasm

Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More

Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights

Assenagon Asset Management S.A. Lowers Stake in Amicus Therapeutics, Inc. $FOLD

Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play

BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal

Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal

BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

Bradley Campbell Sells 77,926 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Zacks Industry Outlook Arcutis, Amicus and ANI

5 Biotech Stocks to Watch for Potential Upside

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?

Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High?

The Best Cheap Stocks Under $10 to Buy in December and 2026

Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock

Can Galafold Continue to Drive Amicus' Top Line in 2026?

Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?